Amino-polyesters: a new class of biomaterials for drug delivery synthesized via ROP of tertiary amino-alcohols

Data di pubblicazione




Data di priorità



Politecnico di Milano, Massachusetts Institute of Technology


Department of Chemistry Materials and Chemical Engineering


Davide Moscatelli, Umberto Capasso Palmiero (PoliMi), Piotr Kowalski, Daniel Anderson (MIT)


The invention consists in a new class of polyesters, biocompatible and biodegradable, bearing ionizable amines, called Amino-Polyesters (APEs), and their synthesis method. APEs are synthetized via Ring opening polymerization of various cyclic monomers using alkoxy bearing tertiary amines as initiators. In addition, since APEs can be easily functionalized, this new class is based on lactides, that permits to obtain a biocompatible polymer and it could be used for drug delivery applications. This design of APEs should significantly decrease potential toxicity of these materials and allow to maximize their efficacy and suitability for drug delivery applications.

Campo di applicazione

The application is related to the pharmaceutic world, since it is a polymeric carriers for the drug delivery for variety of payloads including small molecules, proteins and nucleic acid and messenger RNA. In particular, in the delivery of RNA-based therapeutics, that allows for both transient control of protein and gene expression and permanent editing of the genomic DNA, providing a therapeutic platform suitable for addressing a wide range of diseases.


These cationic polymers, since they are able to condense with nucleic acids into nanoparticles, are well suited and most studied materials for nucleic acid delivery, as like PolyEthylenImini (PEI), poly-amido-amine (PAMAM) and poly-beta-amino-esters (PBAEs). But they have limited efficacy and concerns are still present for the toxicity of them and their degradation derivatives. With this new class of degradable ionizable polymers, the Amino-PolyEsters (APEs) is possible to achieve a really low toxicity and a high efficacy as therapeutic carriers.